Biosimilar Development News

  1. Richter Launched Terrosa®, Its Biosimilar Teriparatide Across Europe

    Gedeon Richter Plc. ("Richter") today announced that it has launched its biosimilar teriparatide, Terrosa® in Europe. The product is approved in adults for the same indications as Eli Lilly's Forsteo®, i.e. used for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

  2. Dr. Reddy's Laboratories Announces The Launch Of Versavo (Bevacizumab Biosimilar) In India

    Dr. Reddy’s Laboratories Ltd. announced recently that it has launched Versavo (bevacizumab), a biosimilar of Roche’s Avastin in India, indicated for the treatment of several types of cancers (metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, metastatic breast cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer). 

  3. U.S. Biosimilars Market To Expand At 54.7% CAGR; Increasing Demand From The Unmet Populace To Create Growth Opportunities, Says Fortune Business Insights

    The U.S. Biosimilars Market will gain momentum from the increasing government support to adopt biosimilars in the healthcare sectors.

  4. Bio-Thera Solutions Initiates Phase I Clinical Trial For BAT2506, A Proposed Biosimilar Of Simponi (Golimumab)

    Bio-Thera Solutions, a clinical-stage pharmaceutical company, recently announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT2506, a proposed biosimilar of Simponi (golimumab), to EU-sourced Simponi in normal healthy volunteers.

  5. Amgen Wins Patent Case On Enbrel® (etanercept)

    Amgen (NASDAQ:AMGN) today announced that the U.S. District Court for the District of New Jersey has ruled in Amgen's favor on validity of the two patents that describe and claim Enbrel® (etanercept) and methods for making it.

  6. Sandoz Will Appeal District Court Of New Jersey Ruling In Biosimilar Erelzi® (etanercept-szzs) US Patent Case

    Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States District Court of New Jersey ruled against Sandoz in patent litigation concerning the Sandoz biosimilar, Erelzi® (etanercept-szzs) for reference medicine Enbrel®* (etanercept).

  7. OneOncology Is Early Adopter Of Biosimilars In U.S.

    OneOncology announced today that its partner practices have already begun administering two biosimilars from Amgen, MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTI™ (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), which were recently made commercially available in the United States.

  8. Global Female Infertility Drugs Market 2019-2023| Introduction Of Biosimilars To Boost Growth| Technavio

    The global female infertility drugs market is expected to post a CAGR of over 5% during the period 2019-2023, according to the latest market research report by Technavio.

  9. Biocon, Mylan Launch Ogivri In Australia

    Biocon Ltd. and Mylan N.V. have announced the launch in Australia of Ogivri (trastuzumab), a biosimilar to Herceptin (trastuzumab), for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).

  10. Coherus BioSciences Reports Victory In Pegfilgrastim Patent Dispute

    Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that the United States Court of Appeals for the Federal Circuit has affirmed the decision of the United States District Court for the District of Delaware that Coherus’ UDENYCA® (pegfilgrastim-cbqv), a pegfilgrastim biosimilar, does not infringe Amgen’s asserted patent.